Keeping an Eye on Neurocrine Biosciences, Inc (NBIX) After Insider Trading Activity

Neurocrine Biosciences, Inc’s filing revealed that its Chief Regulatory Officer Delaet Ingrid unloaded Company’s shares for reported $61695.0 on Jul 10 ’25. In the deal valued at $135.00 per share,457 shares were sold. As a result of this transaction, Delaet Ingrid now holds 4,730 shares worth roughly $0.63 million.

Then, Onyia Jude sold 59,819 shares, generating $7,803,688 in total proceeds. Upon selling the shares at $130.46, the Chief Scientific Officer now owns 18,289 shares.

Before that, INGRID DELAET bought 457 shares. Neurocrine Biosciences, Inc shares valued at $61,014 were divested by the Officer at a price of $133.51 per share.

Goldman initiated its Neurocrine Biosciences, Inc [NBIX] rating to a Buy in a research note published on July 10, 2025; the price target was $182. A number of analysts have revised their coverage, including Needham’s analysts, who increased its forecast for the stock in mid April from “a Hold” to “a Buy”. RBC Capital Mkts also remained covering NBIX and has increased its forecast on April 14, 2025 with a “an Outperform” recommendation from previously “Sector perform” rating. Deutsche Bank started covering the stock on February 11, 2025. It rated NBIX as “a Hold”.

Price Performance Review of NBIX

On Friday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock fall -1.08% to $133.46. Over the last five days, the stock has gained 3.37%. Neurocrine Biosciences, Inc shares have fallen nearly -6.87% since the year began. Nevertheless, the stocks have fallen -2.23% over the past one year. While a 52-week high of $157.98 was reached on 01/30/25, a 52-week low of $84.23 was recorded on 04/09/25.

Levels Of Support And Resistance For NBIX Stock

The 24-hour chart illustrates a support level at 132.04, which if violated will result in even more drops to 130.62. On the upside, there is a resistance level at 134.94. A further resistance level may holdings at 136.42.

How much short interest is there in Neurocrine Biosciences, Inc?

A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-06-13, dropping by -0.53 million shares to a total of 3.5 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 4.03 million shares. There was a decline of -15.29%, which implies that there is a negative sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.